Mathilde Kemula
Overview
Explore the profile of Mathilde Kemula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dauchez A, Dougados M, Kemula M, Regnier E, Aractingi S, Molto A
Rheumatol Int
. 2022 Feb;
42(4):651-657.
PMID: 35152321
The association between psoriatic arthritis (PsA) and psoriasis is well known, but some have suggested that other musculoskeletal (MSK) conditions might also be more common in patients with skin psoriasis...
2.
Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse A, et al.
Acta Derm Venereol
. 2020 Oct;
100(18):adv00316.
PMID: 33111960
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A...
3.
Kemula M
Rev Prat
. 2019 Mar;
68(9):966-971.
PMID: 30869350
Clinical evaluation of a psoriatic patient. Psoriasis is a frequent and burdening inflammatory dermatosis. It affects the quality of life of patients in a deep and sustained way, even if...
4.
Larsen M, Arnaud L, Hie M, Parizot C, Dorgham K, Shoukry M, et al.
Eur J Immunol
. 2011 Jun;
41(9):2596-605.
PMID: 21688259
The ontogenic relationship between pro-inflammatory populations of interleukin-17 (IL-17A)- and/or IL-22-producing T cells and other T-cell subsets is currently unclear in humans. To appreciate T helper cell-lineage commitment, we combined...
5.
Kemula M, Bachelez H
Rev Prat
. 2004 Mar;
54(1):56-9.
PMID: 15049602
Even though systemic immunomodulating or immunosuppressive therapies have shown efficacy in patients with psoriasis, their usage remains restricted to patients with severe, refractory forms of the disease. Indeed, the risk/benefit...